2026 Q1 -tulosraportti
Vain PDF
92 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·25 min sittenI received this email today which I want to share https://news.cision.com/stenocare/r/france-reaches-important-milestone-towards-permanent-legalisation-of-medical-cannabis,c4380842
·3 t sittenSTENOCARE: France reaches important milestone towards permanent legalization of medical cannabis today at 08:01 ∙ News overview (AI) STENOCARE positions its innovative medical cannabis oil, ASTRUM 10-10, for the upcoming permanent French framework for medical cannabis. A crucial regulatory decree, regulating product evaluation, pricing, and reimbursement, has been submitted to France's highest administrative court. This milestone marks an important step in France's transition from a pilot program to a fully regulated, sustainable market. The French reimbursement decree was submitted to the Conseil d'État on July 2, 2026, representing one of the last legal steps before formal adoption. STENOCARE targets the upcoming permanent framework with its ASTRUM 10-10 oil product by leveraging its advanced regulatory dossier and partnership in France. The future permanent framework will require a dual approval: product approval from ANSM and evaluation of the therapeutic benefit for reimbursement from HAS. France's transition to a permanent framework follows a national pilot program for medical cannabis, which has been running since 2021.
Just try to explain to me how a piece of news about France working towards a permanent scheme for medical cannabis relates to you believing that sales in Germany have exploded and that management is deliberately concealing this.- ·21 t sittenstock status Canngo: sold out at two additional pharmacies They were up to 6 pharmacies having the oil in stock, yesterday it was 4 and today it is 2 pharmacies that have it in stock. Everyone who has been sold out since last Thursday has not received the oil in stock yet. I'm not looking to see if new pharmacies are added, because we can easily figure out that they won't, before these pharmacies get the oil in stock again.
·1 päivä sittenAnxious about the financial report, whether to stay or flee. I think it's steadily leaking away all the time.
I primarily believe that the stock is at this level because many are holding onto their shares, and there is clearly someone to buy them all up in the range 0.9-1.1 kr,- And the board has also bought in themselves at the beginning of the year, around price 1.4 kr,- so there is a sign that they (henrik elbæk) expect the price to go significantly above that level in the future.- ·1 päivä sittenStock status Canngo: has sold out at two pharmacies, has gone from 6 to 4 pharmacies Weed.de: has sold out at an additional 1 pharmacy. they have gone from 7 pharmacies to 3 pharmacies. None of the pharmacies that have been sold out since last Thursday, July 29th, have received Weeco Astrum 10/10 in stock yet. Bonus information. I have noticed that the other brands of cannabis oil have also started to be sold out, and these have not come into stock either. Based on this observation, I have started to lean towards the idea that it is sold out due to bottlenecks in delivery, and not because people have stopped buying Weeco Astrum 10/10
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
92 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·25 min sittenI received this email today which I want to share https://news.cision.com/stenocare/r/france-reaches-important-milestone-towards-permanent-legalisation-of-medical-cannabis,c4380842
- ·3 t sittenSTENOCARE: France reaches important milestone towards permanent legalization of medical cannabis today at 08:01 ∙ News overview (AI) STENOCARE positions its innovative medical cannabis oil, ASTRUM 10-10, for the upcoming permanent French framework for medical cannabis. A crucial regulatory decree, regulating product evaluation, pricing, and reimbursement, has been submitted to France's highest administrative court. This milestone marks an important step in France's transition from a pilot program to a fully regulated, sustainable market. The French reimbursement decree was submitted to the Conseil d'État on July 2, 2026, representing one of the last legal steps before formal adoption. STENOCARE targets the upcoming permanent framework with its ASTRUM 10-10 oil product by leveraging its advanced regulatory dossier and partnership in France. The future permanent framework will require a dual approval: product approval from ANSM and evaluation of the therapeutic benefit for reimbursement from HAS. France's transition to a permanent framework follows a national pilot program for medical cannabis, which has been running since 2021.Just try to explain to me how a piece of news about France working towards a permanent scheme for medical cannabis relates to you believing that sales in Germany have exploded and that management is deliberately concealing this.
- ·21 t sittenstock status Canngo: sold out at two additional pharmacies They were up to 6 pharmacies having the oil in stock, yesterday it was 4 and today it is 2 pharmacies that have it in stock. Everyone who has been sold out since last Thursday has not received the oil in stock yet. I'm not looking to see if new pharmacies are added, because we can easily figure out that they won't, before these pharmacies get the oil in stock again.
- ·1 päivä sittenAnxious about the financial report, whether to stay or flee. I think it's steadily leaking away all the time.I primarily believe that the stock is at this level because many are holding onto their shares, and there is clearly someone to buy them all up in the range 0.9-1.1 kr,- And the board has also bought in themselves at the beginning of the year, around price 1.4 kr,- so there is a sign that they (henrik elbæk) expect the price to go significantly above that level in the future.
- ·1 päivä sittenStock status Canngo: has sold out at two pharmacies, has gone from 6 to 4 pharmacies Weed.de: has sold out at an additional 1 pharmacy. they have gone from 7 pharmacies to 3 pharmacies. None of the pharmacies that have been sold out since last Thursday, July 29th, have received Weeco Astrum 10/10 in stock yet. Bonus information. I have noticed that the other brands of cannabis oil have also started to be sold out, and these have not come into stock either. Based on this observation, I have started to lean towards the idea that it is sold out due to bottlenecks in delivery, and not because people have stopped buying Weeco Astrum 10/10
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
92 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·25 min sittenI received this email today which I want to share https://news.cision.com/stenocare/r/france-reaches-important-milestone-towards-permanent-legalisation-of-medical-cannabis,c4380842
- ·3 t sittenSTENOCARE: France reaches important milestone towards permanent legalization of medical cannabis today at 08:01 ∙ News overview (AI) STENOCARE positions its innovative medical cannabis oil, ASTRUM 10-10, for the upcoming permanent French framework for medical cannabis. A crucial regulatory decree, regulating product evaluation, pricing, and reimbursement, has been submitted to France's highest administrative court. This milestone marks an important step in France's transition from a pilot program to a fully regulated, sustainable market. The French reimbursement decree was submitted to the Conseil d'État on July 2, 2026, representing one of the last legal steps before formal adoption. STENOCARE targets the upcoming permanent framework with its ASTRUM 10-10 oil product by leveraging its advanced regulatory dossier and partnership in France. The future permanent framework will require a dual approval: product approval from ANSM and evaluation of the therapeutic benefit for reimbursement from HAS. France's transition to a permanent framework follows a national pilot program for medical cannabis, which has been running since 2021.Just try to explain to me how a piece of news about France working towards a permanent scheme for medical cannabis relates to you believing that sales in Germany have exploded and that management is deliberately concealing this.
- ·21 t sittenstock status Canngo: sold out at two additional pharmacies They were up to 6 pharmacies having the oil in stock, yesterday it was 4 and today it is 2 pharmacies that have it in stock. Everyone who has been sold out since last Thursday has not received the oil in stock yet. I'm not looking to see if new pharmacies are added, because we can easily figure out that they won't, before these pharmacies get the oil in stock again.
- ·1 päivä sittenAnxious about the financial report, whether to stay or flee. I think it's steadily leaking away all the time.I primarily believe that the stock is at this level because many are holding onto their shares, and there is clearly someone to buy them all up in the range 0.9-1.1 kr,- And the board has also bought in themselves at the beginning of the year, around price 1.4 kr,- so there is a sign that they (henrik elbæk) expect the price to go significantly above that level in the future.
- ·1 päivä sittenStock status Canngo: has sold out at two pharmacies, has gone from 6 to 4 pharmacies Weed.de: has sold out at an additional 1 pharmacy. they have gone from 7 pharmacies to 3 pharmacies. None of the pharmacies that have been sold out since last Thursday, July 29th, have received Weeco Astrum 10/10 in stock yet. Bonus information. I have noticed that the other brands of cannabis oil have also started to be sold out, and these have not come into stock either. Based on this observation, I have started to lean towards the idea that it is sold out due to bottlenecks in delivery, and not because people have stopped buying Weeco Astrum 10/10
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt